Home › NCT04716803

Bone Marrow Aspirate Concentrate (BMAC)Treatment for Knee Osteoarthritis

Who can join

Ages 45 to 75 · All sexes

Inclusion Criteria:

1. Kellgren Lawrence radiographic grade IV
2. Need for a total knee arthroscopy by the patients primary care provider/or orthopedist.
3. Persistent pain in target knee that is unresponsive to standard of care including acetametaphine, non-steroidal anti-inflammatory drugs, physical therapy and/or intraarticular corticosteroids and/or hyaluronic acid preparations.
4. Males or females aged 45-75.

Exclusion Criteria:

\-

About the study

The purpose of this study is to investigate the safety and effectiveness of bone marrow aspirate concentrate (BMAC) in patients with moderate to severe osteoarthritis of the knee. BMAC provides a rich source of mesenchymal stem cells (MSCs) and is a stem cell-based therapy that has been reported to preserve or improve the structure of joints. The Angel System is the device used in this study to concentrate bone marrow from the patient and is intended to separate a mixture of blood and bone marrow and collect plasma rich platelets preoperative to a surgical procedure. The goal of this study is to identify whether BMAC can be an effective and safe treatment for patients with osteoarthritis of the knee.

What is being tested

• Bone Marrow Aspirate Concentrate (biological)
• Angel Concentrated Platelet Rich Plasma (cPRP) System (device)

Sponsor: University of California, San Diego · Participants: 10 · Started: Jul 8, 2020

Contact the study team

• Kenneth Kalunian, MD · Phone: 858-246-2381

Official record on ClinicalTrials.gov — NCT04716803

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Oct 3, 2026. Each study sets its own eligibility; the study team decides who can join.